论文部分内容阅读
目的:探讨经鼻腔持续正压通气联合射频消融术治疗阻塞性睡眠呼吸暂停综合征伴阵发性室上性心动过速患者的疗效。方法:回顾我院2010-01-2013-01期间收治的阻塞性睡眠呼吸暂停综合征伴阵发性室上性心动过速的患者,共44例,将其随机平均分为对照组(n=22)和实验组(n=22)。对照组给予射频消融术,而实验组在射频消融术的基础上联用经鼻腔持续正压通气治疗。术后常规随访6个月以观察具体疗效。结果:与对照组相比较,实验组患者的室上性心动过速复发率明显偏低(9.09%∶27.27%)、抗心律失常药物使用率降低(4.54%∶22.73%)、术后6月左室射血分数明显增加[(55.66±5.12)%∶(48.23±4.16%)]、术后6个月左房内径明显缩小[(34.68±3.29)mm∶(38.18±2.21mm)],上述差异均具有统计学意义(P<0.05)。结论:经鼻腔持续正压通气联合射频消融术可明显降低阻塞性睡眠呼吸暂停综合征伴阵发性室上性心动过速患者的症状复发和抗心律失常药使用量,显著改善患者的心脏结构和心脏功能,值得临床大力推广。
Objective: To investigate the efficacy of continuous positive pressure ventilation combined with radiofrequency ablation in the treatment of patients with obstructive sleep apnea syndrome complicated with paroxysmal supraventricular tachycardia. Methods: A total of 44 patients with obstructive sleep apnea syndrome and paroxysmal supraventricular tachycardia admitted to our hospital from January 2010 to January 2013 were randomly divided into control group (n = 22) and experimental group (n = 22). The control group was given radiofrequency ablation, while the experimental group was treated with continuous positive pressure ventilation via nasal cavity on the basis of radiofrequency catheter ablation. Regular follow-up after 6 months to observe the specific effect. Results: Compared with the control group, the recurrence rate of supraventricular tachycardia was significantly lower in the experimental group (9.09%: 27.27%), and the antiarrhythmic drug use rate was decreased (4.54%: 22.73% (55.66 ± 5.12)% (48.23 ± 4.16%)]. The left atrial diameter was significantly reduced at 6 months after operation (34.68 ± 3.29 mm: 38.18 ± 2.21 mm) The differences were statistically significant (P <0.05). CONCLUSIONS: Continuous positive pressure ventilation combined with radiofrequency catheter ablation can significantly reduce the recurrence of symptoms and the use of antiarrhythmic drugs in patients with obstructive sleep apnea syndrome and paroxysmal supraventricular tachycardia, and significantly improve the cardiac structure And heart function, it is worth to clinically promote.